#PharmaStrategy #MedicoMarketing #MedicalAffairs #PharmaLeadership #GLP1 #DiabetesCare #ObesityManagement #HealthcareInnovation #PharmaIndia #EmergingMarkets #MarketAccess #PharmaCommercial #HealthcareLeadership #IndianPharmaLeaders Interesting, Adding diversity to Abbott's usual practices
PlexusDx works with both account types, so you can apply whichever tax-advantaged option you have available
The question of pricing of off-patent semaglutide is one with many opinions and little hard fact at present

PIONEER 1: Daily oral semaglutide versus placebo in people with type 2 diabetes treated with diet and exercise alone PIONEER 2: Daily oral semaglutide versus empagliflozin 25 mg in people with type 2 diabetes PIONEER 3: Daily oral semaglutide versus sitagliptin 100 mg in people with type 2 diabetes PIONEER 4: Daily oral semaglutide versus liraglutide 1.8 mg in people with type 2 diabetes PIONEER 5: Daily oral semaglutide versus placebo in people with type 2 diabetes and moderate renal impairment PIONEER 6 PIONEER 7: Daily oral semaglutide using a flexible dose adjustment based on clinical evaluation versus sitagliptin 100 mg in people with type 2 diabetes PIONEER 8: Effects of daily oral semaglutide versus placebo in people with long duration of type II diabetes treated with insulin OF NOTE: PIONEER 9 and PIONEER 10 were Japanese studies and PIONEER 6 was a cardiovascular safety study

However, BPC-157's regulatory status is complex and may vary by use, jurisdiction, and product category - including FDA regulatory and safety concerns regarding certain BPC-157-related bulk substances used in compounding contexts
This increased usage has created challenges for some people with T2D who have struggled to access certain GLP-1 drugs, as reported by NPR in 2024